Yamashiro K, Oishi A, Hata M, Takahashi A, Tsujikawa A. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials. Jpn J Ophthalmol. 2021;65:741–60.

Article  PubMed  Google Scholar 

Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84.

Article  PubMed  Google Scholar 

Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128:89–99.

Article  PubMed  Google Scholar 

Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomized, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40.

Article  PubMed  CAS  Google Scholar 

Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131:914–26.

Article  PubMed  Google Scholar 

Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127:1345–59.

Article  PubMed  Google Scholar 

Mones J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1050–9.

Article  PubMed  Google Scholar 

Cheung CMG, Guymer RH, Demetriades AM, Margaron P, Quezada Ruiz C, Silverman D, et al. Faricimab in neovascular age related macular degeneration (nAMD): efficacy, safety, and durability through week 48 in the phase 3 TENAYA and LUCERNE trials. The 22nd EURETINA Congress; Sep 1–4, 2022; Hamburg.

Lim JI, Margaron P, Souverain A, Yang M, Shildkrot YE, Kotecha A, et al. Greater reduction in pigment epithelial detachment size with faricimab vs aflibercept during head-to-head dosing in patients with nAMD. The 56th Retina Society Annual Scientific Meeting; Oct 11–14, 2023; New York.

Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141–52.

Article  PubMed  CAS  Google Scholar 

Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020;127:616–36.

Article  PubMed  Google Scholar 

Baumal CR, Bodaghi B, Singer M, Tanzer DJ, Seres A, Joshi MR, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. 2021;5:519–27.

Article  PubMed  Google Scholar 

Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 macular neovascularization. Sci Rep. 2022;12:8195.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yanai H. Statcel—the useful add-in software forms on Excel. 4th ed. Tokyo: OMS; 2015.

Google Scholar 

Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, et al. Effect of high-dose intravitreal Aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol. 2023;141:834–42.

Article  PubMed  Google Scholar 

Mukai R, Matsumoto H, Akiyama H. Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. PLoS ONE. 2021;16:e0259879.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wykoff CC, Matsumoto H, Barakat MR, Karcher H, Lozama A, Mayhook A, et al. Retinal vasculitis or vascular occlusion after brolucizumab for neovascular age-related macular degeneration: a systematic review of real-world evidence. Retina. 2023;43:1051–63.

Article  PubMed  PubMed Central  Google Scholar 

Inoda S, Takahashi H, Maruyama-Inoue M, Ikeda S, Sekiryu T, Itagaki K, et al. Incidence and risk factors of intraocular inflammation after brolucizumab treatment in Japan: a multicenter age-related macular degeneration study. Retina. 2024;44:714–22.

PubMed  CAS  Google Scholar 

Iida T, Takahashi K, Kinfemichael G, Ogura Y. Subpopulation analysis of Japanese patients from brolucizumab HAWK study. The 74th Annual Congress of Japan Clinical Ophthalmology; Oct 13–16, 2020; Tokyo.

Sharma A, Kumar N, Parachuri N, Sharma R, Bandello F, Kuppermann BD, et al. Brolucizumab Immunogenicity. Eye (Lond). 2020;34:1726–8.

Article  PubMed  Google Scholar 

Sharma A, Kumar N, Parachuri N, Singh S, Bandello F, Regillo CD, et al. Understanding retinal vasculitis associated with brolucizumab: complex pathophysiology or Occam’s razor? Ocul Immunol Inflamm. 2021:1–3.

Kusuhara S, Kim KW, Miki A, Nakamura M. Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation. Am J Ophthalmol Case Rep. 2022;26:101521.

Article  PubMed  PubMed Central  Google Scholar 

Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6:465–77.

Article  PubMed  CAS  Google Scholar 

Medrano-Bosch M, Simon-Codina B, Jimenez W, Edelman ER, Melgar-Lesmes P. Monocyte-endothelial cell interactions in vascular and tissue remodeling. Front Immunol. 2023;14:1196033.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Moon BH, Kim Y, Kim SY. Twenty years of anti-vascular endothelial growth factor therapeutics in neovascular age-related macular degeneration treatment. Int J Mol Sci. 2023;24:13004.

Article  PubMed  PubMed Central  CAS  Google Scholar